Literature DB >> 19827837

S-glycosyl primary sulfonamides--a new structural class for selective inhibition of cancer-associated carbonic anhydrases.

Marie Lopez1, Blessy Paul, Andreas Hofmann, Julia Morizzi, Quoc K Wu, Susan A Charman, Alessio Innocenti, Daniela Vullo, Claudiu T Supuran, Sally-Ann Poulsen.   

Abstract

In this paper, we present a new class of carbonic anhydrase (CA) inhibitor that was designed to selectively target the extracellular domains of the cancer-relevant CA isozymes. The aromatic moiety of the classical zinc binding sulfonamide CA inhibitors is absent from these compounds and instead they incorporate a hydrophilic mono- or disaccharide fragment directly attached to the sulfonamide group to give S-glycosyl primary sulfonamides (1-10). The inhibition properties of these compounds at the physiologically abundant human CA isozymes I and II and cancer-associated IX and XII were determined, and all compounds had moderate potency with K(i)s in the micromolar range. We present the crystal structures of anomeric sulfonamides 4, 7, and 10 and the sugar sulfamate drug topiramate in complex with human recombinant CA II. From these structures, we have obtained valuable insights into ligand-protein interactions of these novel carbohydrate-based sulfonamides with CA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19827837     DOI: 10.1021/jm900914e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Advances in Anti-Cancer Drug Development Targeting Carbonic Anhydrase IX and XII.

Authors:  Mam Y Mboge; Robert McKenna; Susan C Frost
Journal:  Top Anticancer Res       Date:  2015

2.  Insights towards sulfonamide drug specificity in α-carbonic anhydrases.

Authors:  Mayank Aggarwal; Bhargav Kondeti; Robert McKenna
Journal:  Bioorg Med Chem       Date:  2012-08-28       Impact factor: 3.641

3.  A sucrose-binding site provides a lead towards an isoform-specific inhibitor of the cancer-associated enzyme carbonic anhydrase IX.

Authors:  Melissa A Pinard; Mayank Aggarwal; Brian P Mahon; Chingkuang Tu; Robert McKenna
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-09-23       Impact factor: 1.056

Review 4.  Probing the surface of human carbonic anhydrase for clues towards the design of isoform specific inhibitors.

Authors:  Melissa A Pinard; Brian Mahon; Robert McKenna
Journal:  Biomed Res Int       Date:  2015-02-24       Impact factor: 3.411

5.  P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors.

Authors:  Joanna Kopecka; Gregory M Rankin; Iris C Salaroglio; Sally-Ann Poulsen; Chiara Riganti
Journal:  Oncotarget       Date:  2016-12-27

6.  An overview of carbohydrate-based carbonic anhydrase inhibitors.

Authors:  Doretta Cuffaro; Elisa Nuti; Armando Rossello
Journal:  J Enzyme Inhib Med Chem       Date:  2020-10-20       Impact factor: 5.051

Review 7.  Experimental Carbonic Anhydrase Inhibitors for the Treatment of Hypoxic Tumors.

Authors:  Claudiu T Supuran
Journal:  J Exp Pharmacol       Date:  2020-12-15

8.  The Glitazone Class of Drugs as Carbonic Anhydrase Inhibitors-A Spin-Off Discovery from Fragment Screening.

Authors:  Sarah L Mueller; Panagiotis K Chrysanthopoulos; Maria A Halili; Caryn Hepburn; Tom Nebl; Claudiu T Supuran; Alessio Nocentini; Thomas S Peat; Sally-Ann Poulsen
Journal:  Molecules       Date:  2021-05-18       Impact factor: 4.411

Review 9.  Cancer Drug Development of Carbonic Anhydrase Inhibitors beyond the Active Site.

Authors:  Srishti Singh; Carrie L Lomelino; Mam Y Mboge; Susan C Frost; Robert McKenna
Journal:  Molecules       Date:  2018-04-30       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.